Triple-Negative Breast Cancer (TNBC) Recruiting Phase 1 Trials for Cetuximab (DB00002)

Also known as: Triple-negative Breast Cancer

IndicationStatusPhase
DBCOND0067309 (Triple-Negative Breast Cancer (TNBC))Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs